Search Results
Aug 19, 2026, 09:14 ET XtalPi Holdings Announces 2026 Interim Results
clinical trials in 2027: ALX001, a bispecific antibody targeting TL1A and IL-23p19 for inflammatory bowel disease; ALX002, a T-cell engager targeting CD19 and BCMA for B-cell-mediated autoimmune diseases including systemic lupus erythematosus and rheumatoid arthritis; and ALX005, a long-acting FcRn-blocking
More news about: XtalPi Holdings Limited
Aug 19, 2026, 08:00 ET PICI Invests More Than $1 Million in Five Early Career Researchers Advancing the Future of Cancer Immunotherapy
Gray-Gaillard of the University of Pennsylvania is investigating how the spatial organization of the tumor microenvironment shapes tumor-infiltrating CD8 T lymphocyte function. Ms. Gray-Gaillard will study the cellular interactions and molecular signals that distinguish tumor-specific T cells from nontumor-specific
More news about: Parker Institute for Cancer Immunotherapy
Aug 19, 2026, 02:03 ET Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
data from its ongoing study evaluating asedebart, an anti-adrenocorticotropic hormone (ACTH) monoclonal antibody, in adults with Cushing's disease (CD). The data were presented orally at the 2026 Endocrine Society's Annual Meeting (ENDO), held from 13–16 June in Chicago, U.S., and showed urinary free
More news about: H. Lundbeck A/S
Aug 19, 2026, 01:59 ET Strong growth from Vyepti® and focused commercial execution drive total revenue growth of +16% CER (+13% CER underlying) in H1 2026
data from its ongoing study evaluating asedebart, an anti-adrenocorticotropic hormone (ACTH) monoclonal antibody, in adults with Cushing's disease (CD). The data were presented orally at the 2026 Endocrine Society's Annual Meeting (ENDO), held from 13–16 June in Chicago, U.S., and showed urinary free
More news about: H. Lundbeck A/S
Aug 18, 2026, 21:00 ET Antengene Presents Key R&D Highlights at the Evercore 2nd China Biotech Summit
proprietary CD3 sequences with fast on/off kinetics to minimize cytokine release syndrome (CRS) and enhance efficacy. These characteristics support the platform's broad applicability across autoimmune disease, solid tumors and hematological malignancies, with programs targeting CD19 x CD3 (ATG-201 for
More news about: Antengene Corporation Limited
Aug 18, 2026, 20:15 ET CARsgen Therapeutics Announces 2026 Interim Results
NMPA.In vivo CAR T-cell products are under development based on the proprietary CARvivo™ platform. An IIT of KJ‑C2529, which targets CD19/CD20 for the treatment of B‑cell malignancies, has been initiated.Dr. Zonghai Li, Founder, Chairman of the Board, Chief Executive
More news about: CARsgen Therapeutics
Aug 18, 2026, 15:00 ET WeirdCo, Developer of Cyberpunk Trading Card Game, Selects Galactic Events Studio's Melee.gg to Power Organized Play
our own standards we need to think about. We've been entrusted with a beloved and meticulously crafted world and cast of characters by our partners at CD PROJEKT RED. They've enabled us to build something truly special with Cyberpunk TCG, and our desire to uphold their reputation for delivering
More news about: Galactic Events Studio
Aug 18, 2026, 10:33 ET Non-Metastatic Prostate Cancer Market to Exhibit Growth at a CAGR of 4% During the Forecast Period (2026-2036), as Pharmaceutical Companies Intensify Development of Advanced Therapies | DelveInsight
serotype 5 capsid protein stimulates a strong inflammatory response in the tumor microenvironment. This mechanism is intended to generate a targeted CD8+ T-cell-mediated immune response against both the injected tumor and distant metastatic lesions, providing a broad anti-tumor effect. CAN-2409 is currently
More news about: DelveInsight Business Research, LLP
Aug 18, 2026, 04:00 ET Ciklum Announces Strategic Partnership with ClickHouse to Accelerate Enterprise Adoption of Agentic AI and Real-Time Analytics
provides a proven adoption journey that minimizes risk and accelerates outcomes.The approach is designed to fit into existing cloud environments, CI/CD pipelines, BI platforms, identity systems, and governance frameworks, delivering reusable IP without introducing proprietary platform lock-in."Enterprises
More news about: Ciklum
Aug 17, 2026, 17:46 ET DOLLARAMA TO REPORT SECOND QUARTER FISCAL 2027 RESULTS
https://register-conf.media-server.com/register/BI6ed40111cd6f4eb5b68f5dfe9792b041
More news about: Dollarama Inc.
Aug 17, 2026, 08:30 ET The9 Limited to Report Second Quarter 2026 Results on August 24, 2026
https://register-conf.media-server.com/register/BI92e5c045cd54492e95c9c81c36fcf980Upon registration, each participant will receive an email containing participant dial-in numbers and
More news about: The9 Limited
Aug 17, 2026, 08:00 ET OncoC4 Announces First Patient Dosing in Phase 1 Clinical Trial of ONC-783 for the Treatment of Advanced Solid Tumors
the NeoCD24 PlatformCD24 is expressed in nearly 70% of human cancers1, along with a significant level of expression also in normal tissues, where it plays a key role in regular cell growth, tissue maintenance, and immune system function. Targeting CD24 as a cancer treatment has been
More news about: OncoC4
Aug 17, 2026, 07:01 ET 30 Million Credit Union Members Are Now Served by AI on the Clutch Platform
platform's connections to the LOS and the core, the systems of record, to carry the request through to completion.Take a member who wants to open a CD and move $15,000 from savings to fund it. Clutch's agents complete the transaction in real time, while the member is still on the call. Or take a member
More news about: WithClutch
Aug 17, 2026, 01:02 ET 再獲「醫藥界諾貝爾獎」提名！晶泰科技孵化企業萊芒生物、默達生物共同入圍2026蓋倫獎
萊芒生物由瑞士洛桑聯邦理工學院（EPFL）唐力教授團隊聯合晶泰科技創立，專注於代謝增強型細胞治療。在晶泰科技的投資孵化與研發賦能下，萊芒生物圍繞T細胞耗竭這一限制免疫治療療效與持久性的關鍵瓶頸構建了獨特的「免疫代謝重編程」技術平台，並基於該平台開發代謝增強型 CD19 CAR-T 產品 META 10-19。在多項研究者發起臨床（IIT）中， META 10-19 僅以常規劑量千分之一的給藥量，在復發或難治性白血病、淋巴瘤患者中取得積極療效；在系統性紅斑狼瘡研究中，患者達到DORIS標準下的停藥緩解，展現出優越的安全性與療效優勢，為讓傳統「百萬一針」的 CAR-T 療法變得「平價」 可及、乃至納入醫保奠定基礎。目前，萊芒生物的
More news about: 晶泰科技
Aug 16, 2026, 20:00 ET AbelZeta Regains Global Rights of C-CAR039 (Prizlon-cel) and Receives FDA Clearance of IND Application in Large B-cell Lymphoma
U.S. Food and Drug Administration (FDA) clearance of IND application for C-CAR039, also known as Prizloncabtagene Autoleucel (Prizlon-cel), an anti-CD20/CD19 bispecific CAR-T, for the treatment of relapsed or refractory (r/r) Large B-cell Lymphoma (LBCL).
More news about: AbelZeta Pharma, Inc.
Aug 14, 2026, 17:02 ET Actinium Pharmaceuticals Announces Actimab-A Intellectual Property and Manufacturing Advances and Provides NYSE American Listing Update
US 12,539,340 for the treatment of solid tumors generally, alone or with checkpoint therapy, expiring 31 October 2043. Together they extend the anti-CD33 franchise beyond hematologic malignancy into solid tumors by targeting the immunosuppressive myeloid cells of the tumor microenvironment rather than
More news about: Actinium Pharmaceuticals, Inc.
Aug 14, 2026, 10:00 ET Phanes Therapeutics Receives FDA Fast Track Designation for Spevatamig in Advanced and Metastatic Biliary Tract Carcinoma
Spevatamig is Phanes' anti-CLDN18.2/CD47 bispecific antibody that functions as an innate immunity enhancer (I2E), an emerging class of immuno-oncology (IO) agents. Spevatamig is currently in Phase 2 studies for the treatment of multiple forms of gastrointestinal cancers.This
More news about: Phanes Therapeutics, Inc.
Aug 14, 2026, 08:51 ET Fannin Receives CDMRP and Faris Foundation Grants to Advance Targeted RapDC Therapy for Ewing Sarcoma
commercial incentives alone are often insufficient."These awards expand Fannin's growing pediatric oncology portfolio, joining Allterum Therapeutics' CD127 antibody program in clinical development for acute lymphoblastic leukemia and Raptamer Therapeutics' RapDC program for osteosarcoma currently in IND-enabling
More news about: Fannin Partners
Aug 13, 2026, 07:30 ET ADC Therapeutics Reports Second Quarter 2026 Financial Results and Provides Operational Updates
excluded and included to arrive at the non-GAAP financial measures.About ZYNLONTA® ZYNLONTA® is a CD19-directed antibody drug conjugate (ADC). Once bound to a CD19-expressing cell, ZYNLONTA is internalized by the cell, where enzymes release a pyrrolobenzodiazepine (PBD) payload. The
More news about: ADC Therapeutics SA
Aug 13, 2026, 07:30 ET Karyopharm Reports Second Quarter 2026 Financial Results and Highlights Continued Progress Toward Myelofibrosis sNDA Submission
all-oral combination of selinexor 40 mg, pomalidomide and dexamethasone (SPd40) in patients with previously treated multiple myeloma who received an anti-CD38 as their immediate prior line of therapy.Anticipated Catalysts and Operational ObjectivesMyelofibrosis FDA
More news about: Karyopharm Therapeutics Inc.
Aug 12, 2026, 14:51 ET CloudSEK Identifies More than 2,500 Organisations Potentially Impacted by AI Supply Chain Exposure Affecting 434,000 Software Pipelines
minutes. Despite the short window, CloudSEK's analysis identified approximately 434,000 CI/CD pipelines, automated systems companies use to build, test and deploy software, potentially connected to the exposure. CI/CD pipelines can automatically download software packages without a developer manually reviewing
More news about: CloudSEK
Aug 12, 2026, 10:31 ET CAR T-Cell Therapy for Acute Lymphoblastic Leukemia Market to Grow Significantly at a CAGR of 6.8% During the Forecast Period (2026-2036), Driven by Emerging Therapies and Expanding Pipeline | DelveInsight
investigational allogeneic, off-the-shelf CAR-T cell therapy targeting CD7. It has been engineered with a fratricide-resistant design to overcome key manufacturing and biological challenges associated with developing CAR-T therapies for CD7-positive hematologic malignancies. In August 2025, Wugen secured
More news about: DelveInsight Business Research, LLP
Aug 12, 2026, 06:30 ET Boulevard Bio Launches with $65 Million from Deerfield and World-Class Founders to Advance Precision Immunology Pipeline
(formerly MTS-128) is a trispecific CD19/BCMA/CD3 T cell engager designed to deliver a durable immune reset in severe B cell-driven autoimmune disease. Its compact design is built to penetrate deeply into tissue and enable a robust response at a low dose. By engaging both CD19 and BCMA, it aims to clear the
More news about: Boulevard Bio
Aug 11, 2026, 12:00 ET CNCF Announces Graduation of Cloud Native Buildpacks, Advancing the Standard for Container Builds
real-world production. Graduation is a recognition well earned and shows how deeply Buildpacks has embedded itself into the cloud native toolkit, from CI/CD pipelines to platform engineering workflows. I look forward to seeing the project continue to evolve and grow its impact across the ecosystem." —
More news about: Cloud Native Computing Foundation
Aug 11, 2026, 07:00 ET ECARX Announces Second Quarter 2026 Unaudited Financial Results
https://register-conf.media-server.com/register/BIe8abcb76ec1e4761a1002346ff30cd05 to receive dial-in information.A replay of the webcast and presentation materials will be available
More news about: ECARX Holdings Inc.